Imugene Ltd
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Leslie Chong
- Full Time Employees
- 14
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 4-6 Bligh Street Sydney NSW Australia 2000
- IPO Date
- Dec 2, 1993
- Website
- imugene.com
- Similar Companies
- Business
- Imugene Limited Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company headquartered in Sydney, Australia, develops innovative immunotherapies that harness the immune system to treat and eradicate tumors in cancer patients; its primary platform technologies include an off-the-shelf allogeneic CAR T cell therapy azer-cel (azercabtagene zapreleucel) targeting CD19 for blood cancers such as relapsed/refractory diffuse large B-cell lymphoma, oncolytic virotherapy CF33 (VAXINIA) for solid tumors in combination with standard-of-care drugs and CAR T therapies, next-generation combination immunotherapy onCARlytics (CF33-CD19) to enhance CAR T responses in solid tumors by presenting CD19 antigen on cancer cells, and B-cell immunotherapies comprising cancer vaccines like HER-Vaxx against HER2 and PD1-Vaxx against PD-1. The company operates primarily in Australia with research facilities, partnerships, and clinical programs across the United States, focusing on both hematologic malignancies and solid tumors for patients with limited treatment options. Founded in 2013 and listed on the ASX since 1993, Imugene advances its pipeline through multiple Phase 1 and 1b clinical trials evaluating safety, efficacy, and combinations with emerging therapies. In recent developments, Imugene completed a $37.5 million capital raise in July 2025, including a $22.5 million placement and $15 million share purchase plan, to fund azer-cel trials in refractory lymphoma patients, and announced outstanding response rates from the Phase 1b azer-cel trial earlier that month; additionally, in April 2024, it entered a strategic manufacturing partnership with Kincell Bio, selling its North Carolina CGMP facility for up to $6 million USD while outsourcing azer-cel production and development to extend cash runway into 2026 and reduce staff by 50 percent.
Company News
Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating
Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort
Shell flags 'significantly higher' gas trading and sells South Africa business - UPDATE
Imugene reports second BTKi cohort response - ICYMI
Imugene CEO details azer-cel trial milestone - ICYMI
Anthropic clears export hurdle for Fable 5, easing a threat to its IPO story
Imugene reports second complete response in azer-cel BTKi cohort
Fed may adopt leaner communications strategy under Warsh, says Deutsche Bank
Nasdaq leads Wall Street higher, Dow Jones notches new record as second quarter ends
Imugene reports first complete response in azer-cel BTKi cohort
FDA Fast Track opens new path for Imugene's Azer-cel - ICYMI
Inside Biotech: FDA fast-track nod sharpens focus on Imugene's off-the-shelf CAR T ambitions
Thor Energy lifted by hydrogen project update
Imugene showcases Azer-Cel progress at ASCO - ICYMI
Dow Jones, Nasdaq close at record levels as Trump says US-Iran peace talks are advancing
Costco's value strategy, membership growth support outlook after strong quarter, says Jefferies
Anthropic confidentially files to go public in the US
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
Small Cap Watch: commercial expansion updates drive news flow
Imugene presents azer-cel data at ASCO as trial expands into new cohort